BR112021019596A2 - Inibidores de aldose redutase - Google Patents
Inibidores de aldose redutaseInfo
- Publication number
- BR112021019596A2 BR112021019596A2 BR112021019596A BR112021019596A BR112021019596A2 BR 112021019596 A2 BR112021019596 A2 BR 112021019596A2 BR 112021019596 A BR112021019596 A BR 112021019596A BR 112021019596 A BR112021019596 A BR 112021019596A BR 112021019596 A2 BR112021019596 A2 BR 112021019596A2
- Authority
- BR
- Brazil
- Prior art keywords
- disorders
- treatment
- treating
- diabetic
- compounds
- Prior art date
Links
- 239000003288 aldose reductase inhibitor Substances 0.000 title 1
- 229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000031229 Cardiomyopathies Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 208000027472 Galactosemias Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 230000036074 healthy skin Effects 0.000 abstract 1
- 210000005003 heart tissue Anatomy 0.000 abstract 1
- 208000037906 ischaemic injury Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 206010040872 skin infection Diseases 0.000 abstract 1
- 230000000451 tissue damage Effects 0.000 abstract 1
- 231100000827 tissue damage Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
a presente invenção refere-se a compostos e composições farmacêuticas dos mesmos, e a métodos para promover envelhecimento saudável da pele, o tratamento de distúrbios da pele, o tratamento de distúrbios cardiovasculares, o tratamento de distúrbios renais, o tratamento de distúrbios de angiogênese, tal como, câncer, tratamento de dano ao tecido, tal como, dano ao tecido não cardíaco, o tratamento de infarto do miocárdio em evolução, o tratamento de lesão isquêmica, e o tratamento de vários outros distúrbios, tais como, complicações decorrentes de diabetes com os compostos e composições da invenção. outros distúrbios podem incluir, porém, não são limitados a, aterosclerose, cardiomiopatia, doença arterial coronária, nefropatia diabética, neuropatia diabética, retinopatia diabética, cardiomiopatia diabética, infecções da pele, doença vascular periférica, acidente vascular cerebral, galactossemia, asma, pmm2-cdg e similares.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962827362P | 2019-04-01 | 2019-04-01 | |
| US201962928735P | 2019-10-31 | 2019-10-31 | |
| PCT/US2020/025928 WO2020205846A1 (en) | 2019-04-01 | 2020-03-31 | Inhibitors of aldose reductase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021019596A2 true BR112021019596A2 (pt) | 2021-11-30 |
Family
ID=70416582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021019596A BR112021019596A2 (pt) | 2019-04-01 | 2020-03-31 | Inibidores de aldose redutase |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220017535A1 (pt) |
| EP (1) | EP3947391A1 (pt) |
| JP (1) | JP2022519944A (pt) |
| KR (1) | KR20220003529A (pt) |
| CN (1) | CN113840825A (pt) |
| AU (1) | AU2020254610A1 (pt) |
| BR (1) | BR112021019596A2 (pt) |
| CA (1) | CA3132136A1 (pt) |
| IL (1) | IL286832A (pt) |
| MX (1) | MX2021011858A (pt) |
| SG (1) | SG11202110590PA (pt) |
| WO (1) | WO2020205846A1 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3658142B1 (en) | 2017-07-28 | 2024-04-17 | Applied Therapeutics, Inc. | Compositions and methods for treating galactosemia |
| EP3966320A4 (en) | 2019-05-07 | 2023-10-25 | University of Miami | TREATMENT AND DETECTION OF HEREDITARY NEUROPATHIES AND ASSOCIATED DISORDERS |
| JP2022552831A (ja) * | 2019-10-08 | 2022-12-20 | アプライド セラピューティクス， インコーポレイテッド | ホスホマンノムターゼ２欠損の処置のためのアルドースレダクターゼ阻害剤 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4939140A (en) * | 1985-11-07 | 1990-07-03 | Pfizer Inc. | Heterocyclic oxophthalazinyl acetic acids |
| WO1989006651A1 (en) * | 1988-01-19 | 1989-07-27 | Pfizer Inc. | 1h-indazole-3-acetic acids as aldose reductase inhibitors |
| US4954629A (en) | 1989-05-11 | 1990-09-04 | Pfizer Inc. | Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof |
| US5304557A (en) | 1989-12-15 | 1994-04-19 | Pfizer Inc. | Substituted oxoophthalazinyl acetic acids and analogs thereof |
| JPH0495025A (ja) | 1990-08-08 | 1992-03-27 | Asahi Chem Ind Co Ltd | アルドースリダクターゼ阻害剤 |
| WO1997008126A1 (en) | 1995-08-28 | 1997-03-06 | American Home Products Corporation | Phenoxy acetic acids as aldose reductase inhibitors and antihyperglycemic agents |
| EP0982306A3 (en) | 1998-08-21 | 2000-07-05 | Pfizer Products Inc. | Polymorph of zopolrestat monohydrate |
| US6570013B2 (en) | 2000-02-16 | 2003-05-27 | Pfizer Inc | Salts of zopolrestat |
| WO2003105864A1 (en) | 2002-06-13 | 2003-12-24 | Board Of Regents, The University Of Texas System | Methods and compositions involving aldose reductase inhibitors |
| US20070021366A1 (en) | 2004-11-19 | 2007-01-25 | Srivastava Satish K | Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use |
| CN101143868A (zh) | 2007-09-04 | 2008-03-19 | 北京理工大学 | 醛糖还原酶抑制剂结构及用途 |
| KR20090084439A (ko) | 2008-02-01 | 2009-08-05 | 부경대학교 산학협력단 | 고삼 추출물 또는 이로부터 분리한 프레닐레이티드플라보노이드 화합물을 함유한 당뇨성 합병증의 예방 또는치료용 조성물 |
| PT2326632T (pt) | 2008-09-06 | 2017-09-05 | Bionevia Pharmaceuticals Inc | Novo cocristal de colina de epalrestat |
| EP4124620A1 (en) * | 2010-07-16 | 2023-02-01 | The Trustees of Columbia University in the City of New York | Aldose reductase inhibitors and uses thereof |
| US8916563B2 (en) * | 2010-07-16 | 2014-12-23 | The Trustees Of Columbia University In The City Of New York | Aldose reductase inhibitors and uses thereof |
| KR101695166B1 (ko) | 2010-11-23 | 2017-01-12 | 대한민국 | 돌나물 추출물을 포함하는 당뇨병 합병증의 예방 또는 치료용 조성물 |
| CN102512407B (zh) | 2011-11-23 | 2014-05-21 | 中山大学 | 一种β-苯丙氨酸类化合物作为醛糖还原酶抑制剂的应用 |
| CN107106537B (zh) | 2015-04-30 | 2020-07-17 | 杭州百诚医药科技股份有限公司 | 芳香族法尼基类化合物及其应用 |
| WO2017038505A1 (ja) | 2015-09-01 | 2017-03-09 | 株式会社村田製作所 | コイル内蔵部品 |
| PT3352754T (pt) * | 2016-06-21 | 2020-12-07 | Univ Columbia | Inibidores da aldose redutase e métodos de seu uso |
| EP3658142B1 (en) * | 2017-07-28 | 2024-04-17 | Applied Therapeutics, Inc. | Compositions and methods for treating galactosemia |
-
2020
- 2020-03-31 EP EP20721069.1A patent/EP3947391A1/en active Pending
- 2020-03-31 AU AU2020254610A patent/AU2020254610A1/en active Pending
- 2020-03-31 CN CN202080036570.XA patent/CN113840825A/zh active Pending
- 2020-03-31 KR KR1020217035362A patent/KR20220003529A/ko unknown
- 2020-03-31 BR BR112021019596A patent/BR112021019596A2/pt unknown
- 2020-03-31 WO PCT/US2020/025928 patent/WO2020205846A1/en active Application Filing
- 2020-03-31 CA CA3132136A patent/CA3132136A1/en active Pending
- 2020-03-31 JP JP2021558814A patent/JP2022519944A/ja active Pending
- 2020-03-31 MX MX2021011858A patent/MX2021011858A/es unknown
- 2020-03-31 SG SG11202110590PA patent/SG11202110590PA/en unknown
-
2021
- 2021-09-29 US US17/489,022 patent/US20220017535A1/en active Pending
- 2021-09-30 IL IL286832A patent/IL286832A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL286832A (en) | 2021-10-31 |
| EP3947391A1 (en) | 2022-02-09 |
| US20220017535A1 (en) | 2022-01-20 |
| JP2022519944A (ja) | 2022-03-25 |
| SG11202110590PA (en) | 2021-10-28 |
| MX2021011858A (es) | 2022-01-18 |
| AU2020254610A1 (en) | 2021-11-18 |
| WO2020205846A1 (en) | 2020-10-08 |
| CA3132136A1 (en) | 2020-10-08 |
| CN113840825A (zh) | 2021-12-24 |
| KR20220003529A (ko) | 2022-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021019596A2 (pt) | Inibidores de aldose redutase | |
| MX2021014938A (es) | Inhibidores de aldosa reductasa y metodos de uso. | |
| BR112012010766A2 (pt) | composições e métodos de tratamento da colite e de outras doenças instestinais | |
| BR112012029656A2 (pt) | composições para uso no tratamento ou diagnóstico de disturbios ósseos e/ou distúrbios cardiovasculares | |
| Xu et al. | Neuroprotection of andrographolide against microglia-mediated inflammatory injury and oxidative damage in PC12 neurons | |
| CO2023005342A2 (es) | Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead para el tratamiento del cancer | |
| EA201491433A1 (ru) | Синтетические миметики апелина для лечения сердечной недостаточности | |
| MX2024009873A (es) | Construcciones de arni para inhibir expresion de asgr1 y metodos para su uso. | |
| IL186487A (en) | Cyclic amines, processes for their preparation, pharmaceutical compositions comprising them and uses thereof | |
| UY33734A (es) | ?Terapia antidiabética vasoprotectora y cardioprotectora?. | |
| BR112018006687A2 (pt) | prevenção, tratamento e reversão de doenças utilizando montantes terapeuticamente eficazes de ácidos graxos ativos | |
| BR112021021477A2 (pt) | Composto, composição farmacêutica e método para tratar uma doença mediada por jak em um indivíduo necessitando do mesmo | |
| TW201613932A (en) | Organic compounds | |
| NO20071259L (no) | Ikke-kardiotoksiske farmasoytiske forbindelser. | |
| BR112022000505A8 (pt) | Compostos de 3,4-(anel fundido em 5)-5-fenil-pirrolidin-2-ona n-substituídos como inibidores de enzima isoqc e/ou qc | |
| AR105752A1 (es) | Métodos para el tratamiento de enfermedades cardiovasculares | |
| Kumar et al. | 1, 2-benzenedicarboxylic acid, bis (2-methyl propyl) ester isolated from Onosma bracteata Wall. inhibits MG-63 cells proliferation via Akt-p53-cyclin pathway | |
| EA201200037A1 (ru) | Терапевтические комбинации никотиновой кислоты и мелдония | |
| Ayatollahi et al. | Antiglycation activity of Otostegia persica (Burm.) Boiss | |
| WO2023122784A3 (en) | Spiros and related analogs for inhibiting yap/taz-tead | |
| AR100642A1 (es) | Anticuerpo antiretroviral dirigida a un retrovirus endógeno humano (herv) | |
| Wang et al. | Influence of hydrogen sulfide on zymogen activation of homocysteine-induced matrix metalloproteinase-2 in H9C2 cardiocytes | |
| Zengin et al. | Phenolic components and assessment of biological properties of Tchihatchewia isatidea Boiss. extracts: Docking and functional approaches for designing novel products | |
| MX2009012644A (es) | Derivados de di(hetero)arilciclohexano, su preparacion, su uso y composiciones farmaceuticas que los comprenden. | |
| BR112022021244A2 (pt) | Composto, e, método de tratamento de uma doença ou distúrbio |